John Lamont Chief Scientist at Randox and also a Senior Manager. John achieved a BSc (Hons) in Biochemistry from The Queen’s University of Belfast (1979) and also an MSc in Clinical Biochemistry from Trinity College Dublin (1983). John worked in clinical biochemistry for 4 years and in Biochemistry Research at Queen’s University before joining Randox Ltd (1984) where he led the development of BAT. John manages molecular biology R&D, external research collaborations, develops strategic alliances with companies and manages the company’s portfolio of IP (co-author of at least 10 patents) and licensing contracts.  
Relevant peer-reviewed publications:
  1. Choi SH*, Ruggiero D*, Sorice R*, …, Lamont J, …Visvikis-Siest S, Seshadri S**, Ciullo M**. Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies. PLoS Genet. 2016 Feb 24;12(2):e1005874.
  2. Rancier M*, Zaaber I*, Stathopoulou MG, Chatelin J, Saleh A, Marmouch H, El Shamieh S, Masson C, Murray H, Lamont J, Fitzgerald P, Mahjoub S, Said K, Tensaout BB, Mestiri S, Visvikis-Siest S. Pro- and anti-angiogenic VEGF mRNAs in autoimmune thyroid diseases. Autoimmunity. 2016 Sep;49(6):366-372.
  3. Zaaber I*, Rancier M*, Stathopoulou MG, Saleh A, Marmouch H, Masson C, Murray H, Kurth MJ, Lamont J, Fitzgerald P, Mahjoub S, Said K, Bel Hadj Jrad Tensaout B, Mestiri S, Visvikis-Siest S. Plasma VEGF-related polymorphisms are implied in autoimmune thyroid diseases. Autoimmunity. 2016 Jun;49(4):229-35.
  4. Saleh A*, Stathopoulou MG*, Dadé S, Ndiaye NC, Azimi-Nezhad M, Murray H, Masson C, Lamont J, Fitzgerald P, Visvikis-Siest S. Angiogenesis related genes NOS3, CD14, MMP3 and IL4R are associated to VEGF gene expression and circulating levels in healthy adults. BMC Med Genet. 2015 Oct 5;16:90.
  5. Azimi-Nezhad M*, Stathopoulou MG*, Bonnefond A, Rancier M, Saleh A, Lamont J, Fitzgerald P, Ndiaye NC, Visvikis-Siest S. Associations of vascular endothelial growth factor (VEGF) with adhesion and inflammation molecules in a healthy population. Cytokine. 2013 Feb; 61(2): 602-7.
  6. Stathopoulou MG*, Bonnefond A*, Ndiaye NC*, Azimi-Nezhad M, El Shamieh S, Saleh A, Rancier M, Siest G, Lamont J, Fitzgerald P, Visvikis-Siest S. A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. J Lipid Res. 2013 Feb; 54(2): 535-41.
  7. Berrahmoune H, Lamont JV, Herbeth B, Lambert D, Masson C, McPhillips M, Fitzgerald PS, Visvikis-Siest S. Association between EGF and lipid concentrations: a benefit role in the atherosclerotic process? Clin Chim Acta. 2009 Apr;402(1-2):196-8.
  8. Berrahmoune H, Herbeth B, Lamont JV, Masson C, Fitzgerald PS, Visvikis-Siest S. Heritability for plasma VEGF concentration in the Stanislas family study. Ann Hum Genet. 2007 Jan;71(Pt 1):54-63.
  9. Berrahmoune H, Lamont JV, Herbeth B, FitzGerald PS, Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: Results from the STANISLAS cohort. Clin Chem. 2006 Mar;52(3):504-10.
  10. McMahon CG, Lamont JV, Curtin E, McConnell RI, Crockard M, Kurth MJ, Crean P, Fitzgerald SP. Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. Am J Emerg Med. 2012; 30 (2):267-74.
  11. Molloy, R., McConnell, R., Lamont, J., FitzGerald, S. Automation of biochip array technology for quality results. Clin Chem Lab Med. 2005; 43(12):1303-13.
  12. Fitzgerald, S P., Lamont, J., McConnell, R I., Benchikh et al O. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem. 2005; 51(7):1165-76.
*equal contribution **equal last authors